Breaking News Headlines Today | Ground News

Cyber Week Sale - Get 40% off Vantage

targetedonc.com image

News from targetedonc.com

Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

FDA expands pirtobrutinib use in chronic lymphocytic leukemia, small lymphocytic lymphoma

Eli Lilly · Ridgecrest

FDA expands pirtobrutinib use in chronic lymphocytic leukemia, small lymphocytic lymphoma

80% Center coverage: 5 sources

The FDA has approved pirtobrutinib for certain adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The new indication applies to adults who previously have been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor, expanding on the 2023 accelerated approval for pirtobrutinib (Jaypirca, Eli Lilly and Co.) for patients who had received at least See the Story

Takeda (NYSE: TAK) Sees 61.9% Durable Rusfertide Response in 52-Week PV VERIFY Study

Takeda (NYSE: TAK) Sees 61.9% Durable Rusfertide Response in 52-Week PV VERIFY Study

100% Right coverage: 1 sources

52-week VERIFY results show 61.9% of PV patients on rusfertide avoided phlebotomy eligibility, while 4-year THRIVE data cut annual phlebotomies 13-fold.See the Story

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.See the Story

Breaking News Topics Related to targetedonc.com